Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor type that is
typically metastatic upon diagnosis. We have a poor understanding of the factors that control …

Small cell lung cancer (SCLC) is an aggressive cancer often diagnosed after it has
metastasized. Despite the need to better understand this disease, SCLC remains poorly …

The coactivator associated arginine methyltransferase (CARM1) promotes transcription, as
its name implies. It does so by modifying histones and chromatin bound proteins. We …

Background Small cell lung cancer (SCLC) is a deadly, high grade neuroendocrine (NE)
tumor without recognized morphologic heterogeneity. However, over 30 years ago we …

Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key
transcription regulators have recently been proposed in cell lines and limited number of …

Small cell lung carcinoma (SCLC) is a neuroendocrine subtype of lung cancer that affects
more than 200,000 people worldwide every year with a very high mortality rate. Here, we …

The discovery of recurrent alterations in genes encoding transcription regulators and
chromatin modifiers is one of the most important recent developments in the study of the …

Loss of the tumor suppressors RB1 and TP53 and MYC amplification are frequent
oncogenic events in small cell lung cancer (SCLC). We show that Myc expression …

Small cell lung cancer (SCLC) is a highly aggressive human tumor with a more than 95%
mortality rate. Its ontogeny and molecular pathogenesis remains poorly understood. We …